Literature DB >> 17169604

Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.

Hema Kothari1, Pranav Kumar, Shyam Sundar, Neeloo Singh.   

Abstract

Resistance to antimonials has become a clinical threat in the treatment of visceral leishmaniasis (VL). Unravelling the resistance mechanism needs attention to circumvent the problem of drug resistance. In one of the resistant isolates, we earlier identified a gene (PG1) implicated in antimony resistance whose localization in the present study was confirmed on the pellicular plasma membrane of the parasite thereby indicating towards membrane modification as a mechanism of resistance in this resistant isolate.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17169604     DOI： 10.1016/j.parint.2006.10.005

Source DB:  PubMed          Journal:  Parasitol Int        ISSN： 1383-5769            Impact factor:   2.230


  10 in total

1.  In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Authors:  Dhiraj Kumar; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

2.  Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.

Authors:  Tatiana R de Moura; Micheli Luize Barbosa Santos; Juciene M Braz; Luis Felipe V C Santos; Matheus T Aragão; Fabricia A de Oliveira; Priscila L Santos; Ângela Maria da Silva; Amélia Ribeiro de Jesus; Roque P de Almeida
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

3.  Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation.

Authors:  Arun Kumar Haldar; Vinod Yadav; Eshu Singhal; Kamlesh Kumar Bisht; Alpana Singh; Suniti Bhaumik; Rajatava Basu; Pradip Sen; Syamal Roy
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

4.  Bioinformatic Analysis of Leishmania donovani Long-Chain Fatty Acid-CoA Ligase as a Novel Drug Target.

Authors:  Jaspreet Kaur; Rameshwar Tiwari; Arun Kumar; Neeloo Singh
Journal:  Mol Biol Int       Date:  2011-07-19

5.  Antimony resistance in leishmania, focusing on experimental research.

Authors:  Fakhri Jeddi; Renaud Piarroux; Charles Mary
Journal:  J Trop Med       Date:  2011-11-17

6.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

7.  Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.

Authors:  Sarah Hendrickx; Annelies Leemans; Annelies Mondelaers; Suman Rijal; Basudha Khanal; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Louis Maes
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

8.  Downregulation of Calcineurin Gene Is Associated with Glucantime(®) Resiatance in Leishmania infantum.

Authors:  Mohammad Bagher Khadem Erfan; Mehdi Mohebali; Elham Kazemi-Rad; Homa Hajjaran; Gholamhossein Edrissian; Setareh Mamishi; Mojtaba Saffari; Reza Raoofian; Mansour Heidari
Journal:  Iran J Parasitol       Date:  2013-07       Impact factor: 1.012

9.  The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.

Authors:  Neeloo Singh; Mitali Chatterjee; Shyam Sundar
Journal:  Parasit Vectors       Date:  2014-12-17       Impact factor: 3.876

Review 10.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.